Randomized, noncomparative, phase II trial of early switch from docetaxel to cabazitaxel or vice versa, with integrated biomarker analysis, in men with chemotherapy-naïve, metastatic, castration-resistant prostate cancer.
Journal of Clinical Oncology.
Times cited: 3
Microtubule inhibitor-based antibody–drug conjugates for cancer therapy.
OncoTargets and Therapy.
Times cited: 28